small molecule

NUVESSA

METRONIDAZOLE

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameNUVESSA
Active ingredientMETRONIDAZOLE
Strength1.3%
Dosage formGEL
RouteVAGINAL
ModalitySmall molecule
FDA approvalMarch 2014
Marketing statusRX

Listed patents

PatentExpiresType
10238634June 2032product
8946276June 2032use U-1664
9198858June 2032use U-1664
10596155June 2032product
8658678June 2028use U-1682
7893097February 2028product
8877792February 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.